Phenotype and genotype in 101 males with X-linked creatine transporter deficiency

dc.contributor.authorvan de Kamp, J.
dc.contributor.authorBratkovic, D.
dc.contributor.authorPoplawski, N.
dc.date.issued2013
dc.description.abstractBackground. Creatine transporter deficiency is a monogenic cause of X-linked intellectual disability. Since its first description in 2001 several case reports have been published but an overview of phenotype, genotype and phenotype–genotype correlation has been lacking. Methods. We performed a retrospective study of clinical, biochemical and molecular genetic data of 101 males with X-linked creatine transporter deficiency from 85 families with a pathogenic mutation in the creatine transporter gene (SLC6A8). Results and conclusions. Most patients developed moderate to severe intellectual disability; mild intellectual disability was rare in adult patients. Speech language development was especially delayed but almost a third of the patients were able to speak in sentences. Besides behavioural problems and seizures, mild to moderate motor dysfunction, including extrapyramidal movement abnormalities, and gastrointestinal problems were frequent clinical features. Urinary creatine to creatinine ratio proved to be a reliable screening method besides MR spectroscopy, molecular genetic testing and creatine uptake studies, allowing definition of diagnostic guidelines. A third of patients had a de novo mutation in the SLC6A8 gene. Mothers with an affected son with a de novo mutation should be counselled about a recurrence risk in further pregnancies due to the possibility of low level somatic or germline mosaicism. Missense mutations with residual activity might be associated with a milder phenotype and large deletions extending beyond the 30 end of the SLC6A8 gene with a more severe phenotype. Evaluation of the biochemical phenotype revealed unexpected high creatine levels in cerebrospinal fluid suggesting that the brain is able to synthesise creatine and that the cerebral creatine deficiency is caused by a defect in the reuptake of creatine within the neurones.
dc.description.statementofresponsibilityJ. M. van de Kamp…D. Bratkovic…N. Poplawski… et al.
dc.identifier.citationJournal of Medical Genetics, 2013; 50(7):463-472
dc.identifier.doi10.1136/jmedgenet-2013-101658
dc.identifier.issn0022-2593
dc.identifier.issn1468-6244
dc.identifier.orcidPoplawski, N. [0000-0002-9372-3325]
dc.identifier.urihttp://hdl.handle.net/2440/82857
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.rights© BMJ Publishing Group Ltd 2013
dc.source.urihttps://doi.org/10.1136/jmedgenet-2013-101658
dc.subjectHumans
dc.subjectBrain Diseases, Metabolic, Inborn
dc.subjectCreatine
dc.subjectNerve Tissue Proteins
dc.subjectRetrospective Studies
dc.subjectGenotype
dc.subjectPhenotype
dc.subjectAdult
dc.subjectChild
dc.subjectMale
dc.subjectGenes, X-Linked
dc.subjectPlasma Membrane Neurotransmitter Transport Proteins
dc.subjectGenetic Testing
dc.subjectX-Linked Intellectual Disability
dc.titlePhenotype and genotype in 101 males with X-linked creatine transporter deficiency
dc.typeJournal article
pubs.publication-statusPublished

Files